Apitegromab: A Myostatin Inhibitor for Spinal Muscular Atrophy

Apitegromab (SRK-015) is an investigational antibody designed to enhance muscle mass and strength, particularly in patients with Spinal Muscular Atrophy (SMA). As the landscape of SMA treatment evolves with gene therapies and survival motor neuron (SMN) protein-targeting drugs, apitegromab represents a complementary strategy: directly addressing the muscle weakness that remains a significant challenge for many individuals with SMA.

Spinal Muscular Atrophy (SMA) is a severe genetic neuromuscular disorder caused by a deficiency in the survival motor neuron (SMN) protein. This deficiency leads to the degeneration of motor neurons, resulting in progressive muscle weakness and atrophy. While SMN-enhancing therapies like nusinersen (Spinraza), onasemnogene abeparvovec (Zolgensma), and risdiplam (Evrysdi) have dramatically improved outcomes, many patients still experience significant residual muscle weakness. This is where apitegromab comes in—by targeting pathways that regulate muscle growth, it aims to further improve motor function and quality of life.

Apitegromab is a human monoclonal antibody that specifically targets and inhibits myostatin.

• Origin: Developed by Scholar Rock, apitegromab (SRK-015) is a product of their proprietary technology aimed at precisely targeting growth factors within the extracellular matrix.

• Structure: As a full-length human monoclonal antibody, it consists of two heavy chains and two light chains, designed for high specificity and potency.

• Target: Its primary target is myostatin, a well-known negative regulator of muscle growth. By neutralizing myostatin, apitegromab aims to unleash the body's natural capacity for muscle development and repair.

The efficacy of apitegromab is being evaluated in clinical trials, most notably the TOPAZ Phase 2 trial. Key aspects include:

• Complementary Effect: Studies are focusing on patients receiving SMN-targeting therapies, to assess apitegromab's ability to provide additional functional benefits.

• Motor Function Improvements: Endpoints include changes in motor function scales such as the Revised Upper Limb Module (RULM) and the Hammersmith Functional Motor Scale-Expanded (HFMSE).

• Muscle Biomarkers: Evaluation of muscle mass and other biomarkers of muscle growth.

Early results from the TOPAZ trial, particularly in non-ambulatory patients with Type 2 and Type 3 SMA, have shown promising trends in improving motor function, suggesting a potential role for apitegromab as an add-on therapy.

Clinical trials to date indicate that apitegromab is generally well-tolerated.

• Adverse Events: Most reported adverse events have been mild to moderate and are not considered to be treatment-related.

• Immunogenicity: As with any monoclonal antibody, immunogenicity (the development of anti-drug antibodies) is monitored, though no significant safety concerns have emerged.

• Specificity: Due to its specific targeting of myostatin, significant off-target effects are not anticipated.

Apitegromab is currently an investigational drug.

• Regulatory Designations: It has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA, highlighting its potential to address an unmet medical need in a serious condition. It also has Orphan Medicinal Product Designation from the European Medicines Agency (EMA).

• Ongoing Trials: Further clinical development, including potential Phase 3 trials, will be crucial to confirm its long-term efficacy and safety profile across different SMA populations.

• Future Outlook: If approved, apitegromab could offer a novel therapeutic avenue for SMA patients, particularly those who have residual muscle deficits despite SMN-restoring treatments, potentially improving their motor milestones and functional independence.

As of 2025/2026, bentracimab has reached several major regulatory milestones:

• FDA Status: It received Breakthrough Therapy Designation and has been under Priority Review following a Biologics License Application (BLA) submission.

• EMA Status: It was granted PRIME (PRIority MEdicines) designation in the EU.

• Orphan Drug Designation: Granted in March 2025 for specific emergency reversal indications.

The future of bentracimab lies in its potential to change the "standard of care" for P2Y12 management, giving clinicians the confidence to use potent antiplatelet agents knowing a "switch" exists to turn them off in an emergency.

At ichorbio, we understand that access to cutting-edge antibodies is vital for preclinical and comparative research.

We supply Apitegromab as a custom research product.

• Delivery Time: 4 weeks.

• Format: Available in various sizes tailored to your laboratory requirements